Takeda(TAK) - 2023 Q2 - Earnings Call Transcript

On oncology, if we can bring new assets like [Indiscernible] fruquintinib that we just in-licensed, that would be terrific. So we are looking at this type of deals to complement our portfolio. We have a very attractive pipeline, but it's more mid-stage. So many of these products in our pipeline will be launched towards the end of the decade. So if we can bring more assets to enrich our portfolio, we'll do. Unidentified Company Representative Company Participants Conference Call Participants Christopher O'Re ...